OMNICELL, INC. (OMCL) Stock
2 members of Congress disclosed 2 trades in OMCL since 2015: 0 purchases and 2 sales, most recently Sara Jacobs (sale, Apr 9, 2021). 6 of the hedge funds AlphaScala tracks reported OMCL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $72.01M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded OMNICELL, INC. (OMCL)?
Most recent: Sara Jacobs (sale, Apr 9, 2021); records start Feb 13, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Sara Jacobs D-CA · House | 2021-04-09 | sale | $50k – $100k |
| Thom Tillis R-NC · Senate | 2015-02-13 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all OMCL political trades →Which hedge funds own OMCL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.73M | $72.01M | -24% |
| Renaissance Technologies Jim Simons (founder) | 596K | $24.76M | +23% |
| D.E. Shaw David Shaw | 287K | $11.94M | -46% |
| Citadel Ken Griffin | 205K | $8.53M | NEW |
| Point72 Steve Cohen | 143K | $5.95M | -23% |
| Bridgewater Associates Ray Dalio | 58K | $2.40M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are OMNICELL, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 17, 26 | Njoku Nnamdi | President & COO | SELL | 3.1K | $114K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →OMCL price chart
Powered by TradingViewWhat does OMNICELL, INC. do?
Omnicell Inc. operates as a provider of medication management solutions and adherence tools within the healthcare industry. Its primary function is to optimize medication management and supply chain processes in healthcare facilities, aiming to enhance safety and efficiency. The company offers automated dispensing systems, pharmacy automation equipment, and software solutions tailored for acute care hospitals, long-term care settings, and other healthcare facilities. Notable features of Omnicell’s offerings include their ability to reduce medication errors, improve workflow efficiency, and facilitate better inventory management. Omnicell plays a significant role in the healthcare sector, impacting hospitals' and pharmacies' ability to comply with stringent regulatory standards while maintaining high levels of patient care. By integrating advanced technologies such as robotics, analytics, and cloud-based solutions, Omnicell supports the digital transformation of medication management, addressing challenges associated with manual processes and medication non-adherence. The company’s market significance is evident as it continually adapts to the evolving needs of healthcare providers, ensuring effective medication administration and promoting patient safety on a global scale.